^
    24h
    A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. (clinicaltrials.gov)
    P2, N=205, Terminated, Vyne Therapeutics Inc. | Trial completion date: Jan 2026 --> Sep 2025 | Active, not recruiting --> Terminated; Business Decision
    Trial completion date • Trial termination
    5d
    Perturbation of BRD4 and p300 activity suppresses super enhancer‑driven KLF6 expression in renal carcinoma. (PubMed, Oncol Rep)
    The effects of JQ1‑mediated BRD4 and A‑485‑mediated p300 inhibition were assessed using cell viability and colony formation assays...However, deacetylation of  individual enhancer regions using CRISPR was insufficient to fully suppress KLF6 transcription, emphasizing the robustness of the KLF6 SE and its modular role in sustaining high KLF6 expression. Overall, the present study deepens the understanding of growth‑promoting KLF6 transcriptional networks in ccRCC and offers insights to support the development of diagnostic or therapeutic strategies.
    Journal
    |
    BRD4 (Bromodomain Containing 4) • HDAC3 (Histone Deacetylase 3)
    |
    JQ-1
    6d
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    7d
    CDAK539A12102: A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer (2025-521000-22-00)
    P1, N=9, Not yet recruiting, Novartis Pharma AG
    New P1 trial
    |
    pelabresib (DAK539) • midazolam hydrochloride
    10d
    CDAK539A12103: A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer (2025-521001-40-00)
    P1, N=9, Not yet recruiting, Novartis Pharma AG
    New P1 trial
    |
    pelabresib (DAK539)
    13d
    Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer. (PubMed, Bioorg Med Chem Lett)
    In this study, we designed and synthesized a series of compounds derived from the histone deacetylase inhibitor (HDACi) Chidamide and the BET bromodomain inhibitor (+)-JQ-1. In the chicken embryo chorioallantoic membrane (CAM) model, 6e inhibited tumor growth and angiogenesis more effectively than chidamide. In summary, 6e demonstrates promising optimization potential as a lead compound for breast cancer therapy.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    JQ-1 • Epidaza (chidamide)
    20d
    A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2029 --> Apr 2028 | Trial primary completion date: Nov 2029 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    pelabresib (DAK539)
    20d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2027 --> Nov 2026
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    22d
    Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (clinicaltrials.gov)
    P2, N=88, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    KRAS mutation • BRCA2 mutation • BRCA1 mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Talzenna (talazoparib) • ZEN-3694
    27d
    An epigenetic bifunctional that toggles between transactivation and repression. (PubMed, bioRxiv)
    We tested these bifunctionals in a FKBP(F36V)-tagged transcription factor reporter system and found bifunctional induced transactivation is relatively common, being observed for bifunctionals with BET ligand JQ1, p300/CBP ligand GNE-781, CDK9 ligand SNS-032, and BRD9 ligand iBRD9. Together, these data establish bifunctionals targeting p300/CBP that toggle between a program of ultra-potent transactivation and repression depending on cellular context. Overall demonstrating that induced proximity with a given ligand does not encode a fixed functional outcome.
    Journal
    |
    CDK9 (Cyclin Dependent Kinase 9)
    |
    JQ-1 • SNS-032
    28d
    A photothermal immune hydrogel dressing for enhanced post-melanoma resection treatment. (PubMed, J Nanobiotechnology)
    In this study, we designed a temperature-tunable photothermal immunotherapy hydrogel dressing (Pd/JQ1@SerMA) to overcome these melanoma postoperative complications...Notably, the hydrogel adaptively fills irregular wound defects, and accelerates postoperative tissue regeneration under mild photothermal stimulation (~ 42 °C). In conclusion, this temperature-tunable photothermal immunotherapeutic hydrogel exhibits remarkable clinical potential for preventing tumor recurrence, combating infection, and promoting wound healing.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • BRD4 (Bromodomain Containing 4)
    |
    PD-L1 expression
    |
    JQ-1
    29d
    Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes. (PubMed, Discov Oncol)
    Three genes (MXRA7, PLEKHG4B and ATP2B4) were identified to construct a SERG-related model in BLCA, which provides a basis for understanding BLCA pathogenesis and new insights into BLCA treatment.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    KRAS G12C • KRAS G12
    |
    JQ-1 • AZD8186 • NU7441